⚕ GalenOps CRO console
← SITE006 (GBR)

SITE006-0389

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE006 (GBR) (Dr. Rossi) · consented 2023-06-22
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 24); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-31 (study day 61); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-20 (study day 81); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 149); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-12-10 (study day 162); relationship: N

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-04-15 (study day 289); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-05-22 (study day 326); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-07-10 (study day 375); relationship: N

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: UNKNOWN; onset 2024-07-12 (study day 377); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.